Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CASP7 | P55210 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417912 | 0.89 | MAPT (0.68) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL10490578 | 0.88 | MEN1 (0.56) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL22588265 | 0.86 | MEN1 (0.53) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL12312338 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL28318461 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL8507803 | 0.85 | MAPT (0.66) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL10633192 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL3277901 | 0.81 | CYP1A2 (0.61) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL17131593 | 0.81 | CA12 (0.63) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL24584894 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| EP-1606265-B1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ALDH1A1 587/4885MAPT 2197/4885MEN1 4147/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ALDH1A1 647/4885MAPT 2178/4885MEN1 4074/4885 |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | ALDH1A1 955/4885MAPT 2574/4885MEN1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.